Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.

Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Alignment with National Health Security Goals: GeoVax’s focus on U.S.-based vaccine production supports HHS’s priority of reducing dependency on foreign pharmaceutical supply chains, ensuring ...

Our fair value estimate is 8.2% lower than Novavax's analyst price target of US$16.43 How far off is Novavax, Inc. (NASDAQ:NVAX) from its intrinsic value? Using the most recent financial data, we'll ...

Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.

The split will allow WBD to take advantage of "broader market opportunities" as they arise, CEO David Zaslav told analysts.

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...